Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

VALSARTAN CRS (15 MG)

VALSARTAN CRS (15 MG)

137862-53-4

DISCOVER
DOCETAXEL TRIHYDRATE CRS (160MG)

DOCETAXEL TRIHYDRATE CRS (160MG)

148408-66-6

DISCOVER
RALOXIFENE HYDROCHLORIDE CRS (110 MG)

RALOXIFENE HYDROCHLORIDE CRS (110 MG)

82640-04-8

DISCOVER
RALOXIFENE FOR PEAK IDENTIFICATION CRS (10 MG)

RALOXIFENE FOR PEAK IDENTIFICATION CRS (10 MG)

82640-04-8

DISCOVER
LOVASTATIN FOR PEAK IDENTIFICATION CRS (20 MG)

LOVASTATIN FOR PEAK IDENTIFICATION CRS (20 MG)

75330-75-5

DISCOVER
CLOBETASONE  BUTYRATE FOR SYSTEM SUITABILITY CRS (20 MG)

CLOBETASONE BUTYRATE FOR SYSTEM SUITABILITY CRS (20 MG)

25122-57-0

DISCOVER
PHENAZONE IMPURITY A CRS (30 MG)

PHENAZONE IMPURITY A CRS (30 MG)

89-25-8

DISCOVER
EPINASTINE HYDROCHLORIDE CRS (20 MG)

EPINASTINE HYDROCHLORIDE CRS (20 MG)

108929-04-0

DISCOVER
Glipizide impurity mixture

Glipizide impurity mixture

NA

DISCOVER
DILTIAZEM FOR SYSTEM SUITABILITY CRS (10 MG)

DILTIAZEM FOR SYSTEM SUITABILITY CRS (10 MG)

33286-22-5

DISCOVER
TERBINAFINE FOR SYSTEM SUITABILITY CRS (10 MG)

TERBINAFINE FOR SYSTEM SUITABILITY CRS (10 MG)

78628-80-5

DISCOVER
GANCICLOVIR IMPURITY MIXTURE CRS (0.005 MG)

GANCICLOVIR IMPURITY MIXTURE CRS (0.005 MG)

NA

DISCOVER